Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Work In Process (2023 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Work In Process for 3 consecutive years, with $246031.0 as the latest value for Q2 2025.

  • On a quarterly basis, Work In Process fell 19.87% to $246031.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $246031.0, a 19.87% decrease, with the full-year FY2024 number at $284883.0, up 2.11% from a year prior.
  • Work In Process was $246031.0 for Q2 2025 at 60 Degrees Pharmaceuticals, down from $284883.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $367587.0 in Q3 2024 to a low of $246031.0 in Q2 2025.
  • A 3-year average of $292629.3 and a median of $284883.0 in 2024 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: grew 2.11% in 2024, then decreased 19.87% in 2025.
  • 60 Degrees Pharmaceuticals' Work In Process stood at $278987.0 in 2023, then increased by 2.11% to $284883.0 in 2024, then decreased by 13.64% to $246031.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Work In Process are $246031.0 (Q2 2025), $284883.0 (Q1 2025), and $284883.0 (Q4 2024).